AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 281 min read$DMRA

Jarrett Jennifer purchased $253K of DMRA

Jarrett Jennifer (Director, President and CEO) purchased 12,500 shares of Damora Therapeutics, Inc. (DMRA) at $20.23 ($0.25M total) on 2026-09-25.

Original reporting
SEC EDGAR · Jarrett Jennifer
Published Sep 28, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 11:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$DMRA
Bullish
medium confidence
Mentioned
$DMRA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DMRABullishLow
01

Why it matters

The purchase modestly raises confidence but unlikely to move price significantly.

02

Market read

Small insider purchase; limited trading relevance.

03

What to watch

Potential upcoming clinical data or financing needs not disclosed.

Relevance 5/10Novelty 4/10Timing: post‑market 2026‑09‑28

Background

Form 4 filing reports insider transactions required by SEC.

Company-level read

Ticker impact

$DMRABullishMedium confidence
Context

Director and CEO Jarrett Jennifer bought 12,500 shares for $252,875, increasing holdings to 512,500 shares.

Expected impact

potential slight upside as market prices in insider buying

Evidence & confidence

Purchase size is modest relative to market cap, but insider status adds weight.

Market effects

Sector

Minor signal for biotech sector insider activity.

Regional

Limited to US biotech investors.

Global

Low global impact.

Counterpoint

What could challenge this read

Insider buying could be routine portfolio rebalancing, not a strong buy signal.

Key entities

  • Company
    Damora Therapeutics, Inc.

    Biotech firm listed on NASDAQ under DMRA.

  • Person
    Jarrett Jennifer

    Director, President and CEO of Damora Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

DMRA insider trading history →

Related articles

OCT 23
$RENTMed

Nexus Capital Management LP (Cohen Michael S, Flesh Daniel E.) purchased $2.2M of RENT (indirect holdings)

Nexus Capital Management LP purchased 632,922 indirectly-held shares of Rent the Runway, Inc. (RENT) at $3.55 ($2.25M total) on 2026-10-21. Filed jointly with Gateway Runway, LLC (Director), Gateway Runway Intermediate Holdings, Inc. (Director), NEXUS SPECIAL SITUATIONS III, L.P. (Director), NEXUS SPECIAL SITUATIONS III (CAYMAN), L.P. (Director), Nexus Special Situations GP III, LP (Director), Nexus Partners III, LLC (Director), Cohen Michael S (Director), Flesh Daniel E. (Director) and Giangiacomo Damian (Director).

SEC EDGAR1 min
OCT 22
$DOLELow

Pale Fire Capital SE (Senkypl Dusan, Barta Jan) purchased $8.6M of DOLE (indirect holdings)

Pale Fire Capital SE purchased 648,356 indirectly-held shares of Dole plc (DOLE) at an average of $13.19 ($13.12–$13.39, $8.55M total) across 3 trades over 2026-10-20 to 2026-10-22. Filed jointly with Pale Fire Capital SICAV a.s. (10% owner), Pale Fire Capital investicni spolecnost a.s. (10% owner), Senkypl Dusan (10% owner) and Barta Jan (10% owner).

SEC EDGAR1 min